Beijing Hotgen Biotech Co., Ltd.

688068

CNE100003P82

Medical Equipment, Supplies & Distribution

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-07-16 pm EDT			5-day change	1st Jan Change
25.56 ^CNY	+0.24%		+1.11%	-37.73%

May. 08	Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on February 8, 2024.	CI
May. 07	Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback announced on February 8, 2024, has closed with 2,893,010 shares, representing 3.24% for CNY 92.02 million.	CI

Oriomis announced that it has received $15.700000 million in funding from Beijing Hotgen Biotech Co., Ltd. and other investors.

January 06, 2022

Oriomis announced that it has received $15,700,000 in funding led by Beijing Hotgen Biotech Co., Ltd. on January 7, 2022. The transaction included participation from other investors.

Latest news about Beijing Hotgen Biotech Co., Ltd.

Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on February 8, 2024.	May. 08	CI
Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback announced on February 8, 2024, has closed with 2,893,010 shares, representing 3.24% for CNY 92.02 million.	May. 06	CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Beijing Hotgen Biotech to Buy Kaijing Gene Technology for 11 Million Yuan	Apr. 16	MT
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on February 8, 2024.	Apr. 02	CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Beijing Hotgen Biotech Co., Ltd. announces an Equity Buyback for CNY 150 million worth of its shares.	Feb. 07	CI
Beijing Hotgen Biotech Co., Ltd. authorizes a Buyback Plan.	Feb. 06	CI
Beijing Hotgen Biotech Co., Ltd.(XSSC:688068) dropped from S&P Global BMI Index	Dec. 18	CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Beijing Hotgen Biotech Co., Ltd.(XSSC:688068) added to S&P Global BMI Index	23-09-18	CI
Hangzhou Oriomics Biotechnology Co., Ltd. announced that it has received CNY 100 million in funding from Shenzhen Dachen Caizhi Venture Capital Management Co., Ltd., Tao Capital, Beijing Hotgen Biotech Co., Ltd. and other investors	23-09-10	CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on September 6, 2022.	23-06-15	CI
Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback announced on September 6, 2022 has closed with 2,861,477 shares, representing 3.12% for CNY 166.45 million.	23-06-12	CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on September 6, 2022.	23-04-06	CI
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on September 6, 2022.	23-01-04	CI
Beijing Hotgen Biotech Unit Secures Registration Certificate For Two Devices	22-12-22	MT
Beijing Hotgen Biotech Gets Registration Certificate for Hepatitis B Assay Kit; Shares Fall 4%	22-11-16	MT
Beijing Hotgen Biotech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-24	CI
Tranche Update on Beijing Hotgen Biotech Co., Ltd.'s Equity Buyback Plan announced on September 6, 2022.	22-10-11	CI
Beijing Hotgen Biotech’s Board Approves Up to $43 Million Share Buyback	22-09-07	MT
Beijing Hotgen Biotech Co., Ltd. announces an Equity Buyback for CNY 300 million worth of its shares.	22-09-06	CI

Chart Beijing Hotgen Biotech Co., Ltd.

Duration

Period

More charts

Beijing Hotgen Biotech Co Ltd is a China-based company mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and instruments. The Company's products mainly include in vitro diagnostic reagents, in vitro diagnostic instruments and biological raw materials. Its products are mainly used in clinical fields such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections, as well as in public safety and other fields such as biosafety, food safety, and disease control and emergency response. The Company primarily conducts its businesses in domestic and overseas markets.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-27 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
BEIJING HOTGEN BIOTECH CO., LTD.	-37.73%	306M
ABBOTT LABORATORIES	-4.90%	182B
MEDTRONIC PLC	-1.36%	104B
DEXCOM, INC.	-7.64%	45.58B
HOYA CORPORATION	+10.44%	46.44B
CENCORA, INC.	+9.63%	44.34B
METTLER-TOLEDO INTERNATIONAL, INC.	+13.63%	29.44B
TERUMO CORPORATION	+20.71%	26.8B
WEST PHARMACEUTICAL SERVICES, INC.	-7.12%	23.82B
STERIS PLC	+4.03%	22.61B